INHALABLE DRY POWDER FORMULATIONS COMPRISING ANGIOGENESIS INHIBITORS

1 . A dry powder formulation suitable for administration via inhalation comprising one or more antibodies or one or more angiogenesis inhibitors, a small molecular API, a stabilizer, and a dispersant.

2 . The formulation according to claim 1 , wherein the angiogenesis inhibitor is a VEGF inhibitor.

3 . The formulation according to claim 1 , wherein the angiogenesis inhibitor is:

(a) aflibercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ponatinib, ramucirumab, ranibizumab, regorafenib, sorafenib, sunitinib, vandetanib, or any combination thereof; or

(ii) an antibody selected from bevacizumab, ramucirumab, and ranibizumab.

4 . The formulation according to claim 1 , wherein the antibody is benralizumab, dupilumab, lebrikizumab, mepolizumab, omalizumab, reslizumab, tralokinumab, oblitoxaximab, palivizumab, panobacumab, raxibacumab, atezolizumab, avelumab, balstilimab, bevacizumab, camrelizumab, cemiplimab, cetuximab, dostarlimab, durvalumab, necitumumab, nimotuzumab, nivolumab, panitumumab, pembrolizumab, prolgolimab, racotumomab, ramucirumab, ranibizumab, retifanlimab, sintilimab, tislelizumab, toripalimab, or any combination thereof.

5 . The formulation according to claim 1 , wherein the small molecular API is selected from cisplatin, carboplatin, topotecan, paclitaxel, erlotinib, or any combination thereof.

6 . The formulation according to claim 1 , wherein the stabilizer is selected from trehalose, mannitol, raffinose, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, inulin, pullulan and mixtures thereof.

7 . The formulation according to claim 1 , wherein the formulation comprises a dispersant selected from L-leucine, tri-leucine, L-isoleucine, arginine, histidine, glycine, and mixtures thereof.

8 . The formulation according to claim 1 , wherein the formulation further comprises a buffer selected from phosphate, tris(hydroxymethyl)aminomethane (TRIS), acetate, glycine, citric acid, carbonate, and mixtures thereof.

9 . The formulation according to claim 1 , wherein the formulation comprises:

1 to 90 wt % of the antibody or angiogenesis inhibitor;

1 wt % to 80 wt % of the small molecular API;

10 wt % to 90 wt % of the stabilizer;

2 wt % to 40 wt % of the dispersant;

and less than 5 wt % of buffer;

wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

10 . The formulation according to claim 1 , wherein the formulation comprises 1 wt % to 50 wt % of angiogenesis inhibitor, 1 wt % to 50 wt % of small molecular API, 10 wt % to 88 wt % of stabilizer, 5 wt % to 30 wt % of dispersant, and optionally up to 5 wt % buffer, wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

11 . The formulation according to claim 1 , wherein the formulation comprises 5 wt % to 40 wt % of bevacizumab, 20 wt % to 80 wt % of trehalose, 10 wt % to 25 wt % of L-leucine, and 5 wt % to 40 wt % of a small molecular API selected from cisplatin, carboplatin, topotecan, paclitaxel, and erlotinib, wherein the overall sum of concentrations of ingredients does not exceed 100 wt %.

12 . The formulation according to claim 1 , wherein the formulation is a spray dried solid dispersion.

13 . The formulation according to claim 1 , wherein the formulation is a spray dried solid dispersion with a particle size distribution of:

d

⁢

90

<

50

⁢

µm

;

(

i

)

d

⁢

50

<

5

⁢

µm

;

or

(

ii

)

d

⁢

90

<

10

⁢

µm

,

d

⁢

50

<

3

⁢

µm

,

and

⁢

d

⁢

10

>

500

⁢

nm

.

(

iii

)

14 . A spray drying process suitable to manufacture a formulation according to claim 1 , wherein the process comprises the following steps:

a) preparing a spray drying solution by dissolution of the angiogenesis inhibitor, the small molecular API, the stabilizer, the dispersant and optionally further ingredients in a spray drying solvent;

b) directing a drying gas at a particular inlet temperature at a particular drying gas flow rate into a drying chamber;

c) directing the spray drying solution at a particular liquid flow rate through an atomizing nozzle into the drying chamber, said drying gas exiting the drying chamber at an outlet temperature; and

d) collecting the obtained particles.

15 . A spray drying process suitable to manufacture a formulation according to claim 1 , wherein the process comprises the following steps:

a1) preparing a first spray drying solution by dissolution of the small molecular API, optionally the stabilizer, optionally the dispersant and optionally further ingredients in a spray drying solvent;

a2) preparing a second spray drying solution by dissolution of the angiogenesis inhibitor, the stabilizer, the dispersant and optionally further ingredients in a spray drying solvent;

b) directing a drying gas at a particular inlet temperature at a particular drying gas flow rate into a drying chamber;

c1) directing the two spray drying solutions simultaneously at particular liquid flow rates through two separate two-fluid atomizing nozzles into the drying chamber, said drying gas exiting the drying chamber at an outlet temperature;

d) collecting the obtained particles.

16 . A capsule comprising a formulation according to claim 1 .

17 . A kit comprising a dry powder inhaler and one or more capsules according to claim 16 .

18 . A blister pack or blister strip comprising a formulation according to claim 1 .

19 . A method of treatment, prevention, delay of progression, and/or maintenance therapy of asthma, COPD, lung infections, cystic fibrosis, or lung cancer, squamous cell carcinoma, epidermoid carcinoma, or large cell carcinoma, which method comprises administering the formulation according to claim 1 to a human being or animal.

20 . The method of treatment according to claim 19 , wherein the formulation is administered via inhalation

(i) twice daily, once daily, twice weekly, once weekly, every two weeks or every three weeks; or

(ii) at a daily overall angiogenesis inhibitor dose of 0.1 mg to 50 mg; or

(iii) every two weeks at a bi-weekly overall angiogenesis inhibitor dose of 1 mg to 200 mg.